Dr. Rahul Kushwah reports

PREDICTMEDIX AI EXPANDS DIAGNOSTIC REACH IN INDIA WITH INNOVATIVE DIABETES NON-INVASIVE SCREENING

Predictmedix AI Inc. has noted a recent technological milestone in its AI (artificial intelligence) product suite -- the ability to detect early signs of diabetes in individuals by analyzing subtle biological indicators, often undetected by conventional methods. Predictmedix AI's expansion into diabetic screening seamlessly aligns with its mission in providing cutting-edge, personalized health care solutions worldwide.

Anticipating India's rising diabetes concerns, Predictmedix AI has developed the non-invasive ability of early detection of the disease. The company, a pioneering force in artificial intelligence-driven diagnostics on a global scale, is excited to introduce its diabetes screening solution to its comprehensive lineup of AI-powered health care offerings. As India faces an escalating diabetes challenge, Predictmedix AI's new initiative aims to transform current modalities for early detection and intervention for this prevalent chronic ailment. India, a country grappling with a significant diabetes burden, has witnessed an alarming surge in diabetes cases in recent years.

According to a study by the Indian Council of Medical Research (ICMR) conducted in 2021, India had an estimated 101 million people with diabetes and 136 million individuals with prediabetes. Instances of diabetes, prediabetes and hypertension have been on the rise in the Asian subcontinent, highlighting the urgency of the situation.

Recognizing the critical need to address this growing health crisis, Predictmedix AI's latest addition to its technology suite holds the promise of ushering in a transformative impact on public health. The company's newly introduced diabetes non-invasive screening solution harnesses the power of advanced AI algorithms to analyze a wide spectrum of pertinent data, encompassing blood flow patterns to monitor volumetric variation in blood circulation, which changes with varying blood sugar levels. Through the identification of subtle indicators, often undetectable by conventional methods, Predictmedix AI's technology demonstrates precision in identifying early signs of diabetes. Timely detection holds paramount importance, enabling health care professionals to initiate prompt interventions, empowering patients to effectively manage their condition and potentially sidestep severe complications.

"Diabetes is a global health challenge, particularly evident in India," remarked Rahul Kushwah, chief operating officer of Predictmedix AI. "Our commitment to enhancing health care outcomes through innovative technology has led us to develop this diabetic screening solution. By harnessing the capabilities of AI to pinpoint potential cases at an early juncture, our aim is to significantly contribute to individual well-being and the larger community."

The significance of early diabetic screening cannot be emphasized enough. Timely detection empowers individuals to make well-informed decisions regarding their health, adopt healthier lifestyles and gain access to appropriate medical interventions. Furthermore, it alleviates the burden on health care systems by mitigating the progression of diabetes-linked complications, such as cardiovascular disorders, kidney afflictions and nerve impairment.

The global market for diabetes diagnostics, estimated at $30.8-billion (U.S.) in 2022, is projected to attain a revised size of $59.4-billion (U.S.) by 2030, reflecting a compound annual growth rate (CAGR) of 8.6 per cent over the analysis period of 2022 to 2030.

About Predictmedix AI Inc.

Predictmedix is an emerging provider of rapid health screening and remote patient care solutions globally. The company's Safe Entry stations -- powered by a proprietary artificial intelligence -- use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including infectious diseases such as COVID-19, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes.

We seek Safe Harbor.